Cerebral proteolysis of amyloid-β peptide: Relevance of insulin-degrading enzyme in Alzheimer's disease;Proteolisis cerebral del peptido amiloide β: Relevancia de la enzima degradadora de insulina en la enfermedad de Alzheimer

Medicina

Volumn 69, Issue 4, 2009, Pages 466-472

  Leal, Maria Celeste ^a   Gamba, Agata Fernandez ^a   Morelli, Laura ^a   Castaño, Eduardo M ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Alzheimer's disease; Amyloid peptide; Insulin degrading enzyme

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; INSULINASE; PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; NERVE DEGENERATION; PATHOGENESIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; AGED; ENZYMOLOGY; HYDROLYSIS; METABOLISM; PATHOLOGY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; HUMANS; HYDROLYSIS; INSULYSIN;

EID: 70349567668     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342 (Pubitemid 28402270)
2. Mangone CA, Arizaga RL. Dementia in Argentina and other Latin-American countries: An overview. Neuroepidemiology 1999; 18: 231-235
3. Mangone CA, Arizaga RL, Allegri RF, Ollari JA. La demencia en Latinoamerica. Rev Neurol Arg 2000; 25: 1085-1112
4. Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in Alzheimer's disease: effect of Ab oligomers at central synapses. Curr Alzheimer Res 2008; 5: 233-243 (Pubitemid 351840275)
5. Morelli L, Llovera R, Ibendahl S, Castaño EM. The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses. Neurochem Res 2002; 27: 1387-1399 (Pubitemid 36014151)
6. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9: 768-778
7. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer's disease: molecular links and clinical implications. Curr Alzheimer Res 2008; 5: 438-447
8. Van Den Heuvel C, Thornton E, Vink R. Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res 2007; 161: 303-316 (Pubitemid 47017411)
9. Dosunmu R, Wu J, Basha MR, Zawia NH. Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother 2007; 7: 887-900. (Pubitemid 47037728)
10. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Aβ by neprilysin. Science 2001; 292: 1550-1552
11. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein and the â-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162-4167 (Pubitemid 36418174)
12. Miller BC, Eckman EA, Sambamurti K, et al. Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003; 100: 6221-6226 (Pubitemid 36576957)
13. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003; 278: 2081-2084 (Pubitemid 36801269)
14. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology and premature death. Neuron 2003; 40: 1087-1093 (Pubitemid 38032786)
15. Roth, RA. Insulysin. In: Barret AJ, Rawlings ND, and Woessner JF, (eds). Handbook of Proteolytic Enzymes. New York: Elsevier Academic Press; 2004. p 871-876.
16. Affholter JA, Hsieh CL, Francke U, Roth RA. Insulin-degrading enzyme: stable expression of the human complementary DNA characterization of its protein product, and chromosomal mapping of the human and mouse genes. Mol Endocrinol 1990; 4: 1125-1135 (Pubitemid 20352010)
17. Baumeister H, Müller D, Rehbein M, Richter D. The rat insulin-degrading enzyme. Molecular cloning and characterization of tissue-specific transcripts. FEBS Lett 1993; 317: 250-254
18. Bertram L, Blacker D, Mullin K, et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000; 290: 2302-2303 (Pubitemid 32041570)
19. Myers A, Holmans P, Marshall H, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000; 290: 2304-2305 (Pubitemid 32041572)
20. Ghosh S, Watanabe RM, Valle TT, et al. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 2000; 67: 1174-1185 (Pubitemid 30816323)
21. Karamohamed S, Demissie S, Volcjak J, et al. Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes 2003; 52: 1562-1567 (Pubitemid 36666215)
22. Feuk L, McCarthy S, Andersson B, Prince JA, Brookes AJ. Mutation screening of a haplotype block around the insulin degrading enzyme gene and association with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2005; 136B: 69-71. (Pubitemid 40917531)
23. Ertekin-Taner N, Allen M, Fadale D, et al. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Ab42 levels and risk for Alzheimer's disease. Hum Mutat 2004; 23: 334-342 (Pubitemid 38461515)
24. Björk BF, Katzov H, Kehoe P, et al. Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. Neurobiol Aging 2007; 28: 1374-1380 (Pubitemid 47081238)
25. Blomqvist ME, Silburn PA, Buchanan DD, et al. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics 2004; 5: 155-159
26. Hong MG, Reynolds C, Gatz M, et al. Evidence that the gene encoding insulin degrading enzyme influences human lifespan. Hum Mol Genet 2008; 17: 2370-2378
27. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid â-protein by degradation. J Biol Chem 1998; 273: 32730-32738 (Pubitemid 28557658)
28. Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid β-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002; 41: 1091-1099 (Pubitemid 34083761)
29. Duckworth WC, Kitabchi AE. Insulin and glucagon degradation by the same enzyme. Diabetes 1974; 23: 536-543
30. Müller D, Baumeister H, Buck F, Richter D. Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. Eur J Biochem 1991; 202: 285-292
31. Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem 2000; 275: 36621-36625
32. Kurochkin IV. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 2001; 26: 421-425
33. Song ES, Juliano MA, Juliano L, Fried MG, Wagner SL, Hersh LB. ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety. J Biol Chem 2004; 279: 54216-54220 (Pubitemid 40053158)
34. Hamel FG, Upward JL, Bennett RG. In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology 2003; 144: 2404-2408
35. Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 2006; 443: 870-874 (Pubitemid 44622699)
36. Akiyama H, Shii K, Yokono K, et al. Cellular localization of insulin-degrading enzyme in rat liver using monoclonal antibodies specific for this enzyme. Biochem Biophy Res Commun 1988; 155: 914-922 (Pubitemid 18230392)
37. Kuo WL, Gehm BD, Rosner MR, Li W, Keller G. Inducible expression and cellular localization of insulin-degrading enzyme in a stably tranfected cell line. J Biol Chem 1994; 269: 22599-22606 (Pubitemid 24273366)
38. Leissring MA, Farris W, Wu X, et al. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 2004; 383: 439-446 (Pubitemid 39546113)
39. Goldfine ID, Williams JA, Bailey AC, et al. Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell protease activity. Diabetes 1984; 33: 64-72.
40. Hamel FG, Mahoney MJ, Duckworth WC. Degradation of intraendosomal insulin by insulin-degrading enzyme without acidification. Diabetes 1991; 40: 436-443
41. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid β-protein. Biochemistry 2005; 44: 6513-6525 (Pubitemid 40593802)
42. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. β-degrading enzymes in Alzheimer's disease. Brain Pathol 2008; 18: 240-252
43. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frölich L, Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 1999; 263:161-164 (Pubitemid 29158953)
44. Morelli L, Llovera RE, Mathov I, et al. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid b vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem 2004; 279: 56004-56013 (Pubitemid 40066608)
45. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313-319
46. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 2007; 28: 824-830 (Pubitemid 46589743)
47. Pérez A, Morelli L, Cresto JC, Castaño EM. Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin-degrading enzyme from Alzheimer disease and control brains. Neurochem Res. 2000; 25: 247-255
48. Shinall H, Song ES, Hersh LB. Susceptibility of amyloid β peptide degrading enzyme to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 2005; 44: 15345-15350 (Pubitemid 41681468)
49. Dorfman VB, Pasquini L, Ruidavets M, et al. Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiol Aging, 2008 Nov 17 [Epub ahead of print].
50. Llovera RE, de Tullio M, Alonso LG, et al. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid b peptide: implications for Alzheimer disease pathogenesis. J Biol Chem 2008; 283: 17039-17048
51. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005; 7: 45-61.
52. Zhao L, Teter B, Morihara T, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004; 24: 11120-11126 (Pubitemid 40012971)